Stock AnalizReplimune Group, Inc. REPL
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2018 · data as of November 13, 2026
Replimune Group, Inc. (REPL) is a healthcare company listed in the US with a market value of about $2.1B.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -53%.
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | — |
| Net income | -$314M | -$247M | -$216M | -$174M | -$118M | -$81M | -$53M | -$31M | -$20M | -$8M |
| Free cash flow | -$285M | -$199M | -$191M | -$130M | -$85M | -$64M | -$67M | -$28M | -$16M | -$7M |
| EPS (diluted) | $-3.38 | $-3.07 | $-3.24 | $-2.99 | $-2.26 | $-1.75 | $-1.54 | $-1.33 | $-3.96 | $-1.55 |
| Net margin | — | — | — | — | — | — | — | — | — | — |
| ROIC | -126.2% | -44.3% | -43.7% | -23.7% | -28.4% | -15.8% | -28.4% | -22.2% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 6 analysts is $23.33, 7% above the current price; targets range from $14.00 to $31.00; the consensus rating is “Buy”; expected EPS is $-2.05 for the fiscal year ending March 31, 2027.
Frequently asked questions
Does Replimune Group pay a dividend?
Not currently.
Is Replimune Group a good stock to buy?
We do not give buy or sell advice. Replimune Group scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.